Skip to main content
SpringerLink
Log in

Will CETP inhibition survive the demise of torcetrapib?

  • Invited Commentary
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Shah PK: Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J 2007, 28:5–12.

    Article  PubMed  CAS  Google Scholar 

  2. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

  3. Harchaoui KE, Steeg WV, Stroes E, Kastelein J: The role of CETP inhibition in dyslipidemia. Curr Atheroscler Rep 2007, 9:125–133.

    Article  PubMed  Google Scholar 

  4. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.

    Article  PubMed  CAS  Google Scholar 

  5. Kastelein J, Leuven SV, Evans G, et al.; The RADIANCE 1 and 2 Study Investigators: Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007, 23:885–894.

    Article  PubMed  CAS  Google Scholar 

  6. Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153–160.

    Article  PubMed  CAS  Google Scholar 

  7. Kastelein JJP, van Leuven SI, Burgess L, et al.; RADIANCE 1 Investigators: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630.

    Article  PubMed  CAS  Google Scholar 

  8. Barter PJ, Kastelein JJ: Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006, 47:492–499.

    Article  PubMed  CAS  Google Scholar 

  9. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.

    Article  PubMed  CAS  Google Scholar 

  10. Watson KE, Srikanthan P, Schreiner PJ, et al.: High HDL-cholesterol levels are paradoxically associated with increased atherosclerosis and increased coronary heart disease (CHD) events in metabolic syndrome subjects: the Multi-ethnic Study of Atherosclerosis (MESA) [abstract 2456]. Circulation 2007, 116:II540b.

    Google Scholar 

  11. Olsson A, Holme I, Tikkanen M, et al.: Higher apo A1, but not higher HDL-C, may be cardioprotective: observational data from the IDEAL trial. J Clin Lipidol 2007, 1:314.

    Google Scholar 

  12. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159–2165.

    Article  PubMed  Google Scholar 

  13. O’Neill E, Sparrow C, Chen Y, et al.: Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor. J Clin Lipidol 2007, 1:367.

    Google Scholar 

  14. Krishna R, Anderson MS, Bergman AJ, et al.: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907–1914.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Health Sciences, Linköping University, Bergviksvägen 48, SE-167 63, Bromma, Sweden

    Anders G. Olsson

  2. Faculty of Health Sciences, Stockholm Heart Center, Bergviksvägen 48, SE-167 63, Bromma, Sweden

    Anders G. Olsson

Authors
  1. Anders G. Olsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anders G. Olsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olsson, A.G. Will CETP inhibition survive the demise of torcetrapib?. Curr Atheroscler Rep 10, 97–99 (2008). https://doi.org/10.1007/s11883-008-0014-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0014-2

Keywords

Search

Navigation